The UK DRI Biomarker Factory was established in 2021 to provide a unique, top-level resource for research groups conducting biomarker projects in the neurodegenerative disease field. The platform has a team of highly trained technical staff and ultrasensitive equipment that can support large scale projects in Alzheimer’s disease and beyond. Amanda Heslegrave, PhD, University College London, London, UK, discusses the technology available at the Biomarker Factory. Regular ELISA platforms, Meso Scale Discovery instruments, and Luminex technology are all available which enable sample multiplexing as well as the development of bespoke custom assays. The most commonly used technology is the Simoa HD-X analyzer, which provides 1000x greater sensitivity for biomarker measurement than traditional immunoassays. Dr Heslegrave comments on the types of projects being undertaken using the service and the increasing capacity to support studies using thousands of samples. This interview took place at the Alzheimer’s Research UK (ARUK) Conference 2023 in Aberdeen, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.